Advertisement
UK markets close in 6 hours 35 minutes

  • FTSE 100

    8,042.23
    +18.36 (+0.23%)
     

  • FTSE 250

    19,681.36
    +81.97 (+0.42%)
     

  • AIM

    751.56
    +2.38 (+0.32%)
     

  • GBP/EUR

    1.1593
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2376
    +0.0026 (+0.21%)
     

  • Bitcoin GBP

    53,470.50
    +99.23 (+0.19%)
     

  • CMC Crypto 200

    1,392.96
    -21.80 (-1.54%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.63
    +0.73 (+0.89%)
     

  • GOLD FUTURES

    2,317.50
    -28.90 (-1.23%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    17,969.72
    +108.92 (+0.61%)
     

  • CAC 40

    8,058.39
    +18.03 (+0.22%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Gilead Sciences Focuses on Its Liver Disease Portfolio

Margaret Patrick
Updated
Gilead Sciences Focuses on Its Liver Disease Portfolio

By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs

Continue reading